行情

HTBX

HTBX

热生物制剂
NASDAQ

实时行情|Nasdaq Last Sale

2.970
-0.060
-1.98%
盘后: 2.970 0 0.00% 16:00 01/18 EST
开盘
3.010
昨收
3.030
最高
3.100
最低
2.930
成交量
16.16万
成交额
--
52周最高
17.00
52周最低
2.930
市值
7,544.85万
市盈率(TTM)
-2.5761
分时
5日
1月
3月
1年
5年
HTBX: RapidVax Unveiled; Elusys Acquisition
By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT
Benzinga · 14小时前
HTBX:RapidVax 亮相; Elusys 收购
By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Since Our Last Update Since our last update, Heat Biologics, Inc. (NASDAQ:HTBX) has announced several major developments including the unveiling of Heat’s RapidVax novel cellular vacc...
Zacks Small Cap Research · 5天前
Heat Biologics Issues New PTX-35 Preclinical Data In Organ Transplantation, Update On HS-110
Heat Biologics Inc (NASDAQ: HTBX) announced promising preclinical data regarding PTX-35. The data has been accepted for publication in the American Journal of Transplantation. A single dose of the preclinical version of PTX-35 (mPTX-35) expanded regulatory...
Benzinga · 6天前
Heat Biologics Announces New PTX-35 Preclinical Data In Organ Transplantation And Provides Update On HS-110
A single dose of the preclinical version of PTX-35 (mPTX-35), was able to expand regulatory T cells (Tregs) and significantly improve disease and graft survival outcomes. Chemically induced pancreatic failure (a model
Benzinga · 6天前
Is Heat Biologics, Inc. (NASDAQ:HTBX) Trading At A 50% Discount?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Heat Biologics, Inc...
Simply Wall St. · 01/04 11:07
Morrisville drugmaker acquiring firm behind anthrax treatment
To further its effort of becoming a leader in biodefense, a Triangle-based firm is merging with a company that contracts with the federal government to produce an anthrax treatment.
American City Business Journals · 2021/12/22 20:00
Heat Biologics To Bolster Presence In Biodefense Space With Elusys Acquisition
Heat Biologics Inc (NASDAQ: HTBX) 
Benzinga · 2021/12/21 17:56
Heat Biologics to acquire biodefense company, Elusys Therapeutics
Heat Biologics (NASDAQ:HTBX) has executed a merger agreement to acquire Elusys Therapeutics, manufacturer of ANTHIM (obiltoxaximab) Injection, pursuant to which Elusys will merge into a wholly owned subsidiary of Heat.
Seekingalpha · 2021/12/21 13:00
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解HTBX最新的财务预测,通过HTBX每股收益,每股净资产,每股现金流等数据分析热生物制剂近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测HTBX价格均价为20.67,最高价位33.00,最低价为15.00。
最高33.00
均价20.67
最低15.00
现价2.970
EPS
实际EPS
预期EPS
-0.28-0.21-0.14-0.07
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 44
机构持股: 283.25万
持股比例: 11.15%
总股本: 2,540.35万
类型机构数股数
增持
15
20.23万
建仓
3
6.34万
减持
7
1.80万
平仓
5
7.23万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-4.74%
制药与医学研究
-1.37%
高管信息
Chairman/President/Chief Executive Officer/Director
Jeffrey Wolf
Chief Financial Officer/Controller/Secretary
William Ostrander
Lead Director/Independent Director
John Prendergast
Independent Director
John Monahan
Independent Director
Edward Smith
暂无数据
HTBX 简况
Heat Biologics, Inc.是一家处于开发阶段的主要开发对抗一系列癌症的异基因现成细胞治疗疫苗的公司。该公司是一家致力于研发T细胞刺激平台技术(如免疫泛抗细胞毒性治疗(ImPACT)和组合泛抗细胞毒性治疗(ComPACT))的免疫肿瘤公司。该公司使用其ImPACT平台技术开发治疗非肌肉浸润性膀胱癌(NMIBC)的产品HS-410(vesigenurtacel-L)和HS-110(viagenpumatucel-L),这两种产品与抗-PD-1检查点抑制剂作为非小细胞肺癌(NSCLC)的潜在治疗方法组合使用。该公司使用其ComPACT平台技术开发作为NSCLC潜在治疗方法的HS-120。该公司正在NMIBC患者中对HS-410进行第二阶段试验,并对与nivolumab(Opdivo)联合治疗NSCLC的HS-110进行第1b阶段试验。

微牛提供Heat Biologics Inc(NASDAQ-HTBX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的HTBX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易HTBX股票基本功能。